Articles tagged with Monotherapies
A team of researchers has identified two proteins critical to the destruction of red blood cells by the Oroya fever pathogen. This discovery paves the way for a potential novel therapy against this deadly neglected tropical disease.
ISM1745, a potentially best-in-class small molecule inhibitor, has been nominated as a preclinical candidate for the treatment of MTAP-deleted cancers. It targets Protein arginine methyltransferase 5 (PRMT5), which is elevated in various cancers and correlates with poor prognostic outcomes.
The EPIC-CAD trial shows that edoxaban monotherapy significantly reduces the risk of primary endpoint, major bleeding, and major ischaemic events compared to dual antithrombotic therapy in patients with high-risk atrial fibrillation and stable coronary artery disease.
Researchers uncovered how combining immunotherapies targeting PD1 and LAG3 enhances CD8+ T cell responses, leading to improved cancer-killing prowess and enhanced survival rates. The studies also revealed that relatlimab is not inert and can be combined with other immunotherapies to improve responses.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
A phase II clinical trial found that combining sEphB4-HSA with pembrolizumab improved outcomes in HPV-negative, EphrinB2-positive head and neck squamous cell carcinoma patients. The combination showed a favorable toxicity profile and activity, particularly among those with HNSCC.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
Researchers analyzed real-world data from over 70,000 HBsAg-positive individuals to study the durability of HBsAg seroclearance. NAs monotherapy was associated with a lower risk of HBsAg seroreversion and more sustained functional cure compared to IFN monotherapy.
The TWILIGHT trial found ticagrelor monotherapy after PCI to have a similar risk of repeat revascularization and MACCE compared to dual antiplatelet therapy. Ticagrelor monotherapy was also associated with lower NACE and clinically-driven revascularization risk.
Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.
A real-world study found that clopidogrel monotherapy was associated with reduced risk of net adverse clinical events and major cardiac events, compared to aspirin monotherapy. Clopidogrel also showed a lower incidence rate of clinically relevant bleeding events.
A Phase 2 clinical trial showed sotorasib can shrink tumors and achieve disease control in heavily pretreated patients with advanced colorectal cancer. The study results exceeded the historic benefits linked to approved therapies, offering new hope for a population with limited treatment options.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Researchers investigated bamlanivimab's effects on mild to moderate COVID-19 patients, finding that higher doses of bamlanivimab significantly reduced severe acute respiratory syndrome coronavirus 2 viral loads. Combination therapy with etesevimab also yielded promising results, highlighting its potential as a treatment option.
A new therapy stimulating immune system response against cancer shows an acceptable safety profile when used alone or with checkpoint inhibitors. BMS-986178 demonstrates manageable adverse events and no dose-limiting toxicities, suggesting its potential as a treatment for patients with solid tumors.
A one-month treatment of dual anti-platelet therapy is safe and as effective as a longer duration of therapy at preventing cardiac events in patients one year after stent placement. This study evaluated the safety and effectiveness of two durations of dual anti-platelet therapy in patients who had drug-eluting stent placement or polyme...
The TWILIGHT trial found that bioabsorbable polymer DES (BP-EES) performed similarly to durable polymer DES (DP-DES) in high-risk patients undergoing PCI. The study also showed a lower frequency of prior MI in BP-EES patients compared to DP-DES patients.
A new study found that early combination therapy using vildagliptin and metformin leads to better blood sugar control and reduced treatment failure rates compared to metformin alone. The study showed a significant reduction in the risk of losing blood sugar control over a 5-year period.
The anti-PD-1 monoclonal antibody pembrolizumab showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC). The study found an objective response rate of 19.3% and a median progression-free survival of 2 months.
A two-week treatment course for adult patients with chronic Chagas disease was shown to be as effective as an eight-week standard treatment in improving sustained parasitological response at six months. The new regimen also significantly reduced side effects, encouraging wider adoption by the medical community.
A two-week treatment course showed similar efficacy and fewer side effects than the standard eight-week treatment in adult patients with chronic Chagas disease. The results bring new hope for people living with this silent disease and could change access to treatment in endemic countries.
A large trial found that long-term single antiplatelet therapy after stenting is relatively safe, but it does not reduce the risk of death or heart attacks compared to standard dual antiplatelet therapy. The study involved over 15,000 patients and followed them for two years.
The full results from the second Phase 3 clinical study of LMTX confirm its efficacy as a monotherapy for mild to moderate Alzheimer's disease. The study showed significant slowing of brain atrophy and functional decline in patients treated with LMTX, while those receiving add-on therapy experienced no significant change.
The tREACH trial found that combination DMARDs (methotrexate, sulfasalazine, and hydroxychloroquine) improve measures of disease activity and functional ability in patients with early rheumatoid arthritis. This suggests an earlier decrease in disease severity and improvements in functional ability compared to monotherapy.
Researchers suggest lower-intensity statin combination therapy as an alternative to high-intensity monotherapy for certain patients. Meanwhile, a medical author argues that personal genome services lack evidence to support their claims and may overwhelm the healthcare system.
Combining varenicline and bupropion for smoking cessation showed increased quit rates in heavier and more dependent smokers. However, the effects were similar in lighter smokers using varenicline alone.
A study found that combination therapy with varenicline and bupropion resulted in better smoking abstinence rates at 12 weeks compared to monotherapy, but not at one year. After one year, the rates were similar, indicating that combination therapy may not provide a significant long-term benefit for smoking cessation.
A combined therapy of adrenocorticotropic hormone, topiramate, vitamin B6, and immunoglobulin effectively improves infantile spasms prognosis. This treatment is superior in cryptogenic children compared to symptomatic ones. The study published in Neural Regeneration Research
Researchers found that patients with pulmonary arterial hypertension (PAH) receiving IV PGI2 combination therapy experienced higher pulmonary vascular resistance, mean number of PAH-related hospitalizations, and dyspnea scores compared to those on monotherapy or non-IV PGI2 combination therapy. This study was presented during CHEST 2012.
The ADACTA trial showed that tocilizumab was more effective than adalimumab in reducing signs and symptoms of rheumatoid arthritis (RA), with significant improvements in DAS28, low disease activity, and ACR20/50/70 responses. Safety results were similar between groups.
A recent study published in JAMA found that combining antibiotics did not improve clinical outcomes for patients with severe sepsis. The study included 298 patients who received either combination therapy or monotherapy, and found no significant difference in organ failure scores or mortality rates between the two groups.
The BIG 1-98 study found that letrozole monotherapy reduced the risk of relapse and death by at least a fifth compared to tamoxifen treatment alone. Long-term follow-up showed significant survival benefits, with women given letrozole having a 20% lower risk of breast cancer recurrence.
A new study published in The Lancet found that platinum-based doublet chemotherapy is associated with improved survival rates for elderly patients with non-small-cell lung cancer. The treatment showed better results compared to monotherapy in patients over 70 years old, suggesting a potential shift in the current treatment strategy for...
Patients with high blood pressure respond better to combination therapy from the start of treatment, with a mean reduction in systolic blood pressure of 6.5 mm Hg. After switching to combination therapy, patients who initially received monotherapy show improvement but not to the same extent as those on combination therapy from the start.
A randomized trial found that oseltamivir monotherapy was both virologically and clinically more effective than the combination of tamiflu and relenza. The study also showed that zanamivir monotherapy had similar effects to the combination
The FDA has accepted historical controls for epilepsy monotherapy studies, allowing patients to receive promising AEDs at effective doses. This design reduces the need for placebo/pseudo-placebo trials and makes the study more attractive to patients and physicians.
The BALANCE study shows that combination therapy with lithium plus valproate is more effective in preventing relapse in people with bipolar I disorder than valproate monotherapy. The benefit is significant and maintained for up to 2 years, regardless of baseline severity of illness.
The majority of malaria endemic countries adopted effective artemisinin combination therapy more than three years ago, but its availability remains low in public and private sectors. Ineffective monotherapies dominate the market share in many countries, with some products costing up to 65 times the minimum daily wage.
A Mayo Clinic-led study finds that infliximab administered alone or in combination with azathioprine is more effective for moderate to severe Crohn's disease than azathioprine alone. The study demonstrates improved patient outcomes, including higher remission rates and mucosal healing.
Bystolic is a once-daily medication that can be used as monotherapy or in combination with other treatments to reduce blood pressure. It selectively blocks the effects of adrenaline at the heart and vasodilates blood vessels, offering a low incidence of traditional beta blocker side effects.
A study found no significant differences in rates of ischemia, death, and other events among patients treated with three anticoagulant regimens. The results suggest that bivalirudin monotherapy or a selective GP IIb/IIIa inhibitor strategy may be safe alternatives to traditional heparin-based regimens.
Concomitant use of nebulized formoterol fumarate and tiotropium shows improved bronchodilation in COPD patients, with fewer adverse events. The study demonstrated significant improvements in lung function and clinical outcomes for COPD patients with moderate to severe disease manifestations.
A combination of sumatriptan and naproxen sodium is more effective in treating migraine than either medication alone, with superior efficacy in headache relief and sustained pain-free response. The treatment targets multiple pathogenic mechanisms in migraine, offering advantages over single therapy.
A phase III study shows Actemra significantly reduces radiographic joint destruction and disease activity scores in patients with early aggressive rheumatoid arthritis. The treatment was generally well-tolerated, with a low incidence of adverse events.
The study presents data on quetiapine fumarate's efficacy in managing symptoms of acute mania in patients with bipolar disorder. The medication achieved significant responses in 48.1% of patients, with a high completion rate compared to the placebo group.
A study by Professor Melissa DelBello found that quetiapine added to divalproex reduced psychotic symptoms in significantly more patients than divalproex alone. The quetiapine combination group also showed improved outcomes without treatment-emergent extrapyramidal symptoms.